SOUTH SAN FRANCISCO, Calif., Nov. 24, 2009 (GLOBE NEWSWIRE) -- Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that Steven R. Deitcher, M.D., President and Chief Executive Officer, will present an overview of the Company at the 21st Annual Piper Jaffray Healthcare Conference on Wednesday, December 2, 2009, at 8:00 a.m. Eastern Time. The conference is being held December 1-2, 2009, in New York City at The New York Palace.
A live audio webcast will be available in the Investor Relations section of Hana's website at www.hanabiosciences.com. An archived replay of the webcast will be available for 10 business days following the presentation.
About Hana Biosciences, Inc.
Hana Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing new, differentiated cancer therapies designed to improve and enable current standards of care. The Company's lead product candidate, Marqibo(R), potentially treats acute lymphoblastic leukemia and lymphomas. The Company has additional pipeline opportunities some of which, like Marqibo, improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity. Additional information on Hana Biosciences can be found at www.hanabiosciences.com.
The Hana Biosciences, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3290